Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
3.525
+0.205 (6.17%)
Mar 14, 2025, 12:31 PM EDT - Market open
Bionano Genomics Revenue
Bionano Genomics had revenue of $6.07M in the quarter ending September 30, 2024, a decrease of -34.83%. This brings the company's revenue in the last twelve months to $33.33M, down -0.82% year-over-year. In the year 2023, Bionano Genomics had annual revenue of $36.12M with 29.90% growth.
Revenue (ttm)
$33.33M
Revenue Growth
-0.82%
P/S Ratio
0.10
Revenue / Employee
$96,901
Employees
344
Market Cap
5.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BNGO News
- 1 day ago - Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML - GlobeNewsWire
- 7 weeks ago - Bionano Announces Effective Date of Reverse Stock Split - GlobeNewsWire
- 2 months ago - Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway - GlobeNewsWire
- 2 months ago - Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis - GlobeNewsWire
- 4 months ago - Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress - GlobeNewsWire